Meyers, Gabrielle http://orcid.org/0000-0001-7821-8745
Hamadani, Mehdi http://orcid.org/0000-0001-5372-510X
Martens, Michael http://orcid.org/0000-0003-3799-681X
Ali, Haris http://orcid.org/0000-0002-9728-7292
Choe, Hannah
Dawson, Peter
Harris, Andrew C.
van Hooren, Eric
Klaassen, Willem
Leifer, Eric
MacMillan, Margaret L. http://orcid.org/0000-0002-0755-0852
van Oosterhout, Ypke
Perez, Lia
Pusic, Iskra
Vo, Phuong http://orcid.org/0000-0002-0823-0244
Levine, John E. http://orcid.org/0000-0002-5611-7828
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (U10HL069294, U24HL138660)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
Xenikos, BV
Article History
Received: 20 September 2021
Revised: 28 October 2021
Accepted: 10 November 2021
First Online: 23 November 2021
Competing interests
: MH: Research Support/Funding: Takeda Pharmaceutical Company; Consultancy: Incyte Corporation; ADC Therapeutics; Pharmacyclics, Omeros, Kite. Speaker’s Bureau: Sanofi Genzyme, AstraZeneca, BeiGene. HA: Consultant and speaker bureau for Incyte, BMS. Research grant from Incyte. IP: Syndax Advisory Board. EvH, WK, and YvO: are employees of Xenikos and own equity in Xenikos. JEL: Research support from Biogen, Incyte, Kamada, and Mesoblast; consulting for Bluebird, Incyte, Jazz, Mesoblast, Omeros, Symbio, Talaris, and X4 Pharmaceuticals; GVHD biomarkers patent and royalties from Viracor.